Eli Lilly and Company (NYSE: LLY) today announced the U.S. Food and Drug Administration (FDA) approved Zepbound® (tirzepatide) as the first and only prescription medicine for adults with moderate ...

Eli Lilly sells one of the most sought-after types of drugs today: weight loss drugs. The company’s Zepbound and Mounjaro have brought in blockbuster revenue, and more growth could be on the ...

The United States Food and Drug Administration says the shortage of Eli Lilly’s Zepbound and Mounjaro drugs has been resolved and that specialty pharmacies and online companies need to stop ...

Eli Lilly & Co. said its weight-loss drug Zepbound outperformed rival Novo Nordisk A/S’s Wegovy in the first head-to-head trial of the two blockbusters. In a study sponsored by Lilly ...

This represents another step in Lilly's historic manufacturing expansion agenda to help more people who depend on its medicines. Since 2020, Lilly has committed more than $23 billion to construct ...

These days, with its revenue booming and a market cap swelling to twice the size of any other pharma company in the U.S., Eli Lilly is doing everything in a big way. One piece of the puzzle that ...

Both Lilly and Novo Nordisk are experiencing unprecedented growth thanks to their weight loss medications. However, Lilly also treats cancer, plaque psoriasis, Alzheimer's disease, eczema ...

ðÿ €üí—Õ×ï+{v7© ( dÓs]}Ý?)TLè¨0B ÓVþo­2îmŒÈ‹± úœÈûPõR==³p8{» HUõ«g{fú ñùÈ OàÈù vq 26.^f ª6[úÞfž B ÛM}ÿ!¤1‹ Ù ôêP>PuÁé)â&ø¿ÑÝ ¦[n ü¸Ø ...

BRISTOL, Wis. — Eli Lilly has announced a $3 billion expansion in Kenosha County to its manufacturing facility acquired earlier this year in Pleasant Prairie. The acquisition, expansion ...

Eli Lilly and Company shared data today seemingly confirming the superior weight loss qualities of its tirzepatide GLP-1 agonist over semaglutide from rival Novo Nordisk A/S. Eli Lilly and Novo ...